Gilead Sciences’ Harvoni
Gilead Sciences’ (GILD) Harvoni is a combination of Ledipasvir 90mg (milligrams) and Sofosbuvir 400mg. Harvoni is approved to treat HCV (Hepatitis C virus) infections.
The above chart shows Harvoni’s revenues since 1Q16.
During 4Q17, Harvoni contributed ~11.0% of Gilead Sciences’ total product sales. Harvoni is approved for use with or without Ribavirin to treat chronic HCV infections of Genotype -1, Genotype-4, Genotype-5, and Genotype-6.
Harvoni’s revenues declined to $644 million during 4Q17—a 60.7% decline compared to revenues of $1.6 billion during 4Q16. Harvoni’s sales declined due to the drug’s patent expiry across all of the major markets.
Harvoni’s US sales decreased to $425 million during 4Q17—compared to $976 million during 4Q16. For European markets, Harvoni reported revenues of $121 million during 4Q17—compared to $363 million during 4Q16. For international markets, Harvoni reported revenues of $98 million during 4Q17—compared to $301 million during 4Q16.
A few other HCV drugs include Viekira Pak from AbbVie’s (ABBV) portfolio, Olysio from Johnson & Johnson’s (JNJ) portfolio, Daklinza from Bristol-Myers Squibb’s (BMY) portfolio, and Pegasys from Genentech’s portfolio.
Other HCV drugs
As we discussed earlier, Gilead Sciences’ HCV portfolio also includes Sovaldi, Epclusa, and Vosevi. Vosevi reported revenues of $170 million during 4Q17 due to US sales of $150 million and European sales of $17 million.